Comparative Pharmacology
Head-to-head clinical analysis: DOXY 100 versus RONDOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXY 100 versus RONDOMYCIN.
DOXY 100 vs RONDOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by reversibly binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases and reducing cytokine production.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg daily.
150 mg orally twice daily or 300 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 18-22 hours in adults; prolonged to 20-30 hours in renal impairment.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may extend to 20-30 hours in severe renal impairment.
Renal (approximately 40% as unchanged drug) and fecal/biliary (approximately 50-60% as inactive metabolites and unchanged drug).
Renal (40-50% unchanged), biliary/fecal (10-20% as metabolites and unchanged drug). Approximately 30% undergoes enterohepatic circulation.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic